Pulse Biosciences (PLSE)
(Delayed Data from NSDQ)
$15.54 USD
-0.02 (-0.13%)
Updated Aug 29, 2025 04:00 PM ET
After-Market: $15.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PLSE 15.54 -0.02(-0.13%)
Will PLSE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PLSE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PLSE
PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment
PLSE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PLSE
PLSE forms 50 Day Moving Average Support on August 28
Is PLSE showing upside potential? 50 Day Moving Average Support shows up after declining 1.83%
50 Day Moving Average Support appears for PLSE after 0.13% move
The technical outlook for PLSE is unchanged after it falls 6.27% on August 27
Pulse Biosciences Publishes Promising Thyroid Study Results